Your browser doesn't support javascript.
loading
A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients.
Huang, Ya-Hui; Liang, Kung-Hao; Chien, Rong-Nan; Hu, Tsung-Hui; Lin, Kwang-Huei; Hsu, Chao-Wei; Lin, Chih-Lang; Pan, Tai-Long; Ke, Po-Yuan; Yeh, Chau-Ting.
Afiliación
  • Huang YH; Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
  • Liang KH; Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
  • Chien RN; Liver Research Unit, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
  • Hu TH; Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
  • Lin KH; Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
  • Hsu CW; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Lin CL; Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
  • Pan TL; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
  • Ke PY; Liver Research Center, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
  • Yeh CT; Liver Research Unit, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
Sci Rep ; 7(1): 523, 2017 03 31.
Article en En | MEDLINE | ID: mdl-28364124
With the availability of potent antiviral therapies, complete suppression of hepatitis B virus (HBV) replication and total eradication of hepatitis C virus (HCV) can now be achieved. Despite these advances, hepatocellular carcinoma (HCC) still develops in a substantial proportion of cirrhotic patients, suggesting that host factors remain critical. Dysregulation of miRNAs is noted in many cancers, and circulating miRNAs can be readily assayed. In this study, we aimed to develop a circulating miRNA signature to assess the risk of HCC in cirrhotic patients. We first discovered that HBV- and HCV-related cirrhotic patients had distinguishable circulating miRNA profiles. A cohort of 330 cirrhotic patients was then compared against a cohort of 42 early HCC patients with complete remission. A score comprising 5 miRNAs and a binary etiology variable was established that was capable of differentiating between these two groups (AUC = 72.5%, P < 0.001). The 330 cirrhotic patients were further stratified into high- and low-risk groups, and all patients were longitudinally followed for 752 (11-891) days. Of them, 19 patients developed HCC. The high-risk group had significantly higher cumulative HCC incidence (P = 0.038). In summary, a circulating miRNA-based score was developed that is capable of assessing HCC risks in cirrhotic patients.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / MicroARN Circulante / Cirrosis Hepática / Neoplasias Hepáticas Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / MicroARN Circulante / Cirrosis Hepática / Neoplasias Hepáticas Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Año: 2017 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Reino Unido